# US 2019/0314361 A1 · THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314361 A1
- Document ID: US20190314361A1
- Status: Published application
- Kind: A1
- Application number: 16/383,026
- Filed: 2019-04-12
- Published: 2019-10-17
- Earliest claimed: 2018-04-13
- Applicants: Athenex Therapeutics Limited
- Inventors: Min-Fun Rudolf KWAN; Johnson Yiu-Nam LAU; Wing Kai CHAN; Michael P. SMOLINSKI
- Web page: https://patentgrep.com/patent/US20190314361A1

## CPC

- A61K 31/4725: containing further heterocyclic rings
- A61K 31/337: having four-membered rings, e.g. taxol
- A61P 35/00: Antineoplastic agents
- A61P 39/00: General protective or antinoxious agents
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/4858: {Organic compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from an angiosarcoma.

## Claims

### Claim 1

A method for treating an angiosarcoma in a subject in need thereof, comprising:
a. oral administration of paclitaxel at an amount of about 205 mg/m2 to the subject once a day and for 3 times a week; and
b. oral administration of Compound A:
to the subject once a day and for 1-3 times a week, and
wherein Compound A is administered prior to the paclitaxel.

### Claim 2 (depends on 1)

The method of claim 1, comprising oral administration of paclitaxel on consecutive days.

### Claim 3 (depends on 1)

The method of claim 1, comprising oral administration of Compound A at an amount of about 15 mg.

### Claim 4 (depends on 1)

The method of claim 1, comprising oral administration of Compound A for 3 times a week.

### Claim 5 (depends on 1)

The method of claim 1, comprising oral administration of Compound A on consecutive days.

### Claim 6 (depends on 1)

The method of claim 1, comprising oral administration of Compound A at an amount of about 15 mg and for 3 times a week.

### Claim 7 (depends on 6)

The method of claim 6, comprising oral administration of paclitaxel on consecutive days.

### Claim 8 (depends on 6)

The method of claim 6, comprising oral administration of Compound A on consecutive days.

### Claim 9 (depends on 6)

The method of claim 6, wherein Compound A is administered about an hour prior to the paclitaxel.

### Claim 10 (depends on 1)

The method of claim 1, wherein the angiosarcoma is cutaneous angiosarcoma.

### Claim 11

A method for treating an angiosarcoma in a subject in need thereof, comprising:
a. oral administration of paclitaxel at an amount of about 205 mg/m2 to the subject once a day and for 3 times a week for a first duration, and at a second amount less than 205 mg/m2 to the subject once a day and for 3 times a week for a second duration;
b. oral administration of Compound A:
to the subject once a day and for 1-3 times a week, and
wherein Compound A is administered prior to the paclitaxel.

### Claim 12 (depends on 11)

The method of claim 11, wherein the second amount is about 165 mg/m2.

### Claim 13 (depends on 11)

The method of claim 11, wherein the second amount is about 130 mg/m2.

### Claim 14 (depends on 11)

The method of claim 11, comprising oral administration of Compound A at an amount of about 15 mg and for 3 times a week.

### Claim 15 (depends on 11)

The method of claim 11, wherein the angiosarcoma is cutaneous angiosarcoma.

### Claim 16

A method for treating an angiosarcoma in a subject in need thereof, comprising:
a. oral administration of paclitaxel at an amount of about 205 mg/m2 to the subject once a day and for 3 times a week for a first duration, at a second amount less than 205 mg/m2 to the subject once a day and for 3 times a week for a second duration, and at a third amount less than the second amount to the subject once a day and for 3 times a week;
b. oral administration of Compound A:
to the subject once a day and for 1-3 times a week, and
wherein Compound A is administered prior to the paclitaxel.

### Claim 17 (depends on 16)

The method of claim 16, wherein the second amount is about 165 mg/m2.

### Claim 18 (depends on 16)

The method of claim 16, wherein the third amount is about 130 mg/m2.

### Claim 19 (depends on 16)

The method of claim 16, comprising oral administration of Compound A at an amount of about 15 mg and for 3 times a week.

### Claim 20 (depends on 16)

The method of claim 16, wherein the angiosarcoma is cutaneous angiosarcoma.
